← Back to patent-cliff list
FXR-0906
Tier C — Watch / tradeFXR-0906
-
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Nucleic acid drug
Type
Targets：APOC3
Indications (approved)：Hypertriglyceridaemia
Regional status
US
-
EU
-
China
Phase II
2026-09-17
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of FXR-0906?
Approved indications include: Hypertriglyceridaemia.
When does the FXR-0906 patent expire?
No public expiry year is available for FXR-0906 yet; this page updates once verified.
How do I get a quote for FXR-0906 intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-28